Spark layoffs won't derail Philadelphia's biotech surge, city official says
Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large.
'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Technical.ly Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.'
Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene.
From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors.
'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said.
Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia.
Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative.
'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Technical.ly
24-06-2025
- Technical.ly
How Philly's BioLattice is making the jump from grants to VC
For nearly two years, has hosted its monthly segment, Speaking, on WURD Radio's 'Reality Check' with Tonya Pendleton. Earlier this month, WURD cancelled the show after a round of layoffs. Winning pitch competitions and getting industry recognition don't always lead to funding. For Amelia Zellander, founder and CEO of the tissue engineering startup BioLattice, it took six years to get the 'proper funding' to pursue the biotechnology, which she finally secured at the end of 2023. Innovations like biomaterial to repair the front layer of the eye — an alternative to traditional cornea transplants — can be risky to develop, she said. In the current climate of risk-averse investors, that makes biotech money difficult to land. It was ultimately federal funding (the same programs now in limbo under the Trump administration) that made Zellander's initial research possible. Now she's seeking venture capital to maintain that momentum. 'My journey with this company in this form really started in 2017,' Zellander told reporter Sarah Huffman on Speaking, a monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. 'I applied for federal funding multiple times before I finally got the Phase One [National Science Foundation Small Business Innovation Research ] grant.' The funding served as a launch pad. Since starting a research partnership with Lehigh University, BioLattice has landed an $80,000 first-place prize at a pitch competition. More recently, Zellander was named Startup of the Year at BioLabs' third annual investor day. BioLattice is continuing its growth trajectory as a member of the inaugural HiveBio accelerator cohort. This is helping build the company's brand and supporting its path to securing investors, per Zellander. 'I have been getting a little bit of funding, but I'm just still in the battle to build my reputation,' she said, 'to build the trust with investors, and to present the need.' While positive recognition is useful in general, it doesn't always translate into dollars, Zellander said. As BioLattice gears up to raise its next $2 million to support the prototyping phase, she's hoping to make sure it can turn the accolades into securing VCs. BioLattice is currently in a preclinical, prototype stage. Its CorneaClear technology is compatible with rabbit eyes, and now needs more testing to conduct a formal animal study. 'Storytelling is the biggest thing,' Zellander said. 'Investors want to know: How are they going to get their investment back?'
Technical.ly
08-06-2025
- Technical.ly
Most companies don't IPO, so here's how to plan for your likely exit
The most important day of an entrepreneur's journey might be the one when it ends. The big question: Will it end on your terms? That's the dilemma behind most startup exits, whether they take place through a merger, acquisition or an initial public offering (IPO). Experts put that distinction front and center during the 2025 Builders Conference session titled 'M&A or IPO: What is Your Company's Destination?' Moderated by Mike Ravenscroft of the University System of Maryland's Maryland Momentum Fund, the conversation featured attorney Kim Klayman of Ballard Spahr and Alexis Grant, founder of the M&A-focused newsletter They Got Acquired. Together, they laid out a candid, often under-explored roadmap of what founders really need to know about exiting — and why waiting until it's too late to plan is a mistake. 'Think about it early,' Grant said. 'Gives you more options.' The numbers are clear, Ravenscroft noted: Only a tiny fraction of companies ever go public, and even among VC-backed firms, IPOs are rare. The vast majority of exits happen via mergers and acquisitions (M&A). The panelists agreed that the perception gap around what makes an exit 'successful' can obscure the reality of its true impact. A $7 million sale might be life-changing for a bootstrapped founder with majority ownership. But if that same company had raised venture capital at a high valuation, the founder might walk away with little or nothing. 'If someone raises $5 million and they sell for $5 million, they probably didn't get any money,' Grant said. That disconnect is even more stark during economic downturns or slower capital markets. Klayman pointed to the increase in smaller companies acquiring other small firms — sometimes simply to pad revenue, not gain technology. But these all-stock or acqui-hire (in which a company gets acquired for their talent) deals can mask another story: Sometimes, the best-case scenario is simply survival. 'The reality is most companies end up in an M&A situation, even if it's a multi-generational business,' Klayman said. 'It does end up a lot of times in an M&A transaction if there is no succession plan.' The hardest parts that too few talk about Asked what founders need to prepare for, both panelists were unequivocal: The due diligence process is brutal. 'For many [founders], due diligence ends up being a second job,' Grant said, adding: 'You also have to keep running the business, and you want to run it in a way that performance does not drop, because that's the worst thing that can happen when you're going through a deal.' That's why both she and Klayman emphasized the need to 'get your house in order' — and do so early. From knowing who owns the IP to having clean cap tables and documented promises of equity shares, small oversights can kill a deal late in the game. 'I have actually seen one deal die because the whole company was built on this one piece of software, and that's what the buyer wanted,' Klayman said. 'And it was like, a software developer did it 25 years earlier, and they didn't paper it because it wasn't that important. And the deal just died.' She advised founders to use tools like Carta or diligence-prep software to identify red flags before a transaction is even on the table. Attorneys can help, but so can platforms that flag missing consents or unsigned option grants. 'Being organized is like 95% of the battle,' Klayman said. The stories behind the headlines Of course, learning these details can be difficult when many companies don't discuss them soon after an M&A takes place. The panel also pulled back the curtain on how mergers and acquisitions are framed in public — and how different the internal reality can be. Grant, whose company profiles founder-led exits, said PR statements often overhype vague synergies and downplay job losses or underwhelming returns. She added that sellers are often far more candid a year or two post-sale. 'Most of the stories we write, they're usually at least six months after the acquisition has taken place,' Grant said. 'The seller is more open to sharing real details at that point.' Klayman agreed: Sometimes the announcements make it seem like someone got a bunch of money, when usually the investors, even if they're paid first, 'are getting like 10 cents on the dollar,' she said. 'I don't think that people want those types of transactions to happen,' she said, 'but when they do happen, it takes effort and, I think, actually responsible founders to make it happen.' All emphasized that outcomes must be evaluated in context. Founders may sell to give their team stability, find a new role or offload a company responsibly instead of shutting down. What matters, they said, is alignment between a founder's goals and their investors' expectations. The closing message to founders was clear: Plan for your endgame from the beginning. Think through potential paths — and not just the flashy ones. Ask investors what their expectations are. Build a network that includes not just mentors and peers, but service providers who understand exits and won't charge you just to ask questions. 'If you don't know what success looks like, you're going to be poor no matter what,' Ravenscroft said, 'because you won't know it if you get it.'
Technical.ly
09-05-2025
- Technical.ly
Spark layoffs won't derail Philadelphia's biotech surge, city official says
Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics. Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large. 'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.' Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene. From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors. 'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said. Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia. Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative. 'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
